Cardio Diagnostics Brings Molecular Precision to a Blind Spot in Coronary Heart Disease Detection

Coronary heart disease (CHD) remains the leading cause of death in the United States, yet the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO) reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors, and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means many who appear healthy go on to develop CHD and experience preventable cardiac events such as a heart attack.

For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable.

Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics, fields that examine how genes are expressed and regulated at the molecular level. These tests aim to bring molecular precision to a blind spot in CHD detection by analyzing biological markers that traditional risk assessments overlook. The company's approach could shift the paradigm from relying on population-based calculators to personalized molecular diagnostics.

The announcement highlights a critical gap in current cardiovascular care: the reliance on tools with limited sensitivity means that many at-risk individuals are not identified until after a cardiac event. By incorporating epigenetic and genetic insights, Cardio Diagnostics seeks to improve early detection and enable proactive intervention. For more information, visit the company's newsroom at https://ibn.fm/CDIO.

This development underscores the potential of precision medicine to address longstanding challenges in public health. As the leading cause of death, CHD demands innovative solutions that go beyond traditional risk factors. Cardio Diagnostics' molecular tests represent a step toward closing the detection gap and reducing preventable deaths.